Trius Therapeutics, which is developing an oral antibiotic for serious staph infections, kicked off a new IPO roadshow this week after temporarily postponing its IPO in March to adjust the Phase 3 protocol for its lead drug. The San Diego, CA-based biotech,...read more
Alimera Sciences, which is developing an injectable implant to treat eye diseases, will see its quiet period end on Monday, May 31st. On April 21st, the company raised $72.1 million by offering 6.6 million shares at $11, below the range of $15-$17. Credit...read more
Alimera Sciences, which is developing an injectable implant to treat eye diseases, raised $72 million by offering 6,550,000 shares at $11.00, below the range of $15.00 to $17.00. Alimera Sciences plans to list on the NASDAQ under the symbol ALIM. Credit Suisse...read more
Biotech Trius Therapeutics back on IPO calendar for week of July 26
Trius Therapeutics, which is developing an oral antibiotic for serious staph infections, kicked off a new IPO roadshow this week after temporarily postponing its IPO in March to adjust the Phase 3 protocol for its lead drug. The San Diego, CA-based biotech,...read more
Alimera Sciences quiet period ends May 31
Alimera Sciences, which is developing an injectable implant to treat eye diseases, will see its quiet period end on Monday, May 31st. On April 21st, the company raised $72.1 million by offering 6.6 million shares at $11, below the range of $15-$17. Credit...read more
Alimera Sciences prices IPO at $11.00, below the range
Alimera Sciences, which is developing an injectable implant to treat eye diseases, raised $72 million by offering 6,550,000 shares at $11.00, below the range of $15.00 to $17.00. Alimera Sciences plans to list on the NASDAQ under the symbol ALIM. Credit Suisse...read more
8 IPOs planned for the week of Apr 19
The following IPOs are expected to price this week:
Alimera Sciences (ALIM), which is developing an injectable implant to treat eye diseases, plans to raise $96 million by...read more